The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …

Immune-checkpoint blockers (ICBs) have revolutionized oncology and firmly established the
subfield of immuno-oncology. Despite this renaissance, a subset of cancer patients remain …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the
triggering of an aberrant host immune response, more so than on direct virus-induced …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

Clinically relevant immunological biomarkers that discriminate between diverse
hypofunctional states of tumor-associated CD8+ T cells remain disputed. Using multiomics …

Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

Type I interferons (IFNs) facilitate cancer immunosurveillance, antitumor immunity and
antitumor efficacy of conventional cell death-inducing therapies (chemotherapy/radiotherapy …

CD8+ T cell activation via immune checkpoint blockade (ICB) is successful in microsatellite
instable (MSI) colorectal cancer (CRC) patients. By comparison, the success of …

Type I interferons (IFNs) comprise of pro-inflammatory cytokines created, as well as sensed,
by all nucleated cells with the main objective of blocking pathogens-driven infections. Owing …